
-
Esperion NASDAQ:ESPR Through scientific and clinical excellence, and a deep understanding of cholesterol biology, the experienced Lipid Management Team at Esperion is committed to developing new LDL-C lowering medicines that will make a substantial impact on reducing global cardiovascular disease, the leading cause of death around the world.
Location: 3891 Ranchero Dr Ste 150, Michigan, 48108-2837, US | Website: www.esperion.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
689.8M
Cash
144.8M
Avg Qtr Burn
-5.914M
Short % of Float
14.77%
Insider Ownership
1.00%
Institutional Own.
65.70%
Qtr Updated
12/31/24
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Nexlizet (bempedoic acid and ezetimibe) Details Hypercholesterolemia, Atherosclerotic cardiovascular disease , Heterozygous familial hypercholesterolemia, Cardiovascular risk reduction | Approved Quarterly sales | |
Nexletol (bempedoic acid) Details Heterozygous familial hypercholesterolemia, Atherosclerotic cardiovascular disease , Hypercholesterolemia | Approved Quarterly sales | |
Bempedoic acid Details Pediatric Heterozygous and Homozygous Familial Hypercholesterolemia | Phase 3 Initiation |